This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, A. E. Articles by Houston, A. M. Search for Related Content PubMed PubMed Citation Articles by Ryan, A. E. Articles by Houston, A. M.

Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo

¹ Department of Medicine, Cork University Hospital, and ² Alimentary Pharmabiotic Centre, National University of Ireland Cork, Cork, Ireland

Requests for reprints: Aileen M. Houston, Department of Medicine, Clinical Science Building, Cork University Hospital, Wilton, Cork, Ireland. Phone: 353-21-490-1226; Fax: 353-21-434-5300; E-mail: a.houston{at}ucc.ie.

Fas ligand (FasL/CD95L) is a transmembrane protein belonging to the tumor necrosis factor superfamily that can trigger apoptotic cell death following ligation to its receptor, Fas (CD95/APO-1). Expression of FasL may help to maintain tumor cells in a state of immune privilege by inducing apoptosis of antitumor immune effector cells—the "Fas counterattack." However, the ability of FasL to mediate tumor immune privilege is controversial due to studies that indicate FasL has both pro- and anti-inflammatory activities. To resolve this controversy and functionally define the role of FasL in tumor immune evasion, we investigated if suppression of endogenously expressed FasL in colon tumor cells resulted in reduced tumor development and improved antitumor immune challenge in vivo. Specifically, FasL expression in CMT93 colon carcinoma cells was down-regulated following stable transfection with a plasmid encoding antisense FasL cDNA. Down-regulation of FasL expression had no effect on tumor growth in vitro but significantly reduced tumor development in syngeneic immunocompetent mice in vivo. Tumor size was also significantly decreased. Reduced FasL expression by tumor cells led to increased lymphocyte infiltration. The overall level of neutrophils present in all of the tumors examined was low, with no difference between the tumors, irrespective of FasL expression. Thus, down-regulation of FasL expression by colon tumor cells results in an improved antitumor immune challenge in vivo, providing functional evidence in favor of the "Fas counterattack" as a mechanism of tumor immune evasion.

This article has been cited by other articles:

				C. Steinmann, M. L. Landsverk, J. M. Barral, and D. Boehning Requirement of Inositol 1,4,5-Trisphosphate Receptors for Tumor-mediated Lymphocyte Apoptosis J. Biol. Chem., May 16, 2008; 283(20): 13506 - 13509. [Abstract] [Full Text] [PDF]

				L. Zheng, R. Sharma, F. Gaskin, S. M. Fu, and S.-T. Ju A Novel Role of IL-2 in Organ-Specific Autoimmune Inflammation beyond Regulatory T Cell Checkpoint: Both IL-2 Knockout and Fas Mutation Prolong Lifespan of Scurfy Mice but by Different Mechanisms J. Immunol., December 15, 2007; 179(12): 8035 - 8041. [Abstract] [Full Text] [PDF]

				B. Fingleton, K. J. Carter, and L. M. Matrisian Loss of Functional Fas Ligand Enhances Intestinal Tumorigenesis in the Min Mouse Model Cancer Res., May 15, 2007; 67(10): 4800 - 4806. [Abstract] [Full Text] [PDF]

				G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin. Cancer Res., April 1, 2006; 12(7): 2359s - 2365s. [Abstract] [Full Text] [PDF]